Thermo Fisher to sell microbiology unit to Astorg for $1.075 billion, aiming to optimize portfolio and reinvest for future growth.
Thermo Fisher Scientific Inc., a global leader in scientific services and solutions, has entered into a definitive agreement to divest its microbiology business to Astorg, a prominent pan-European private equity firm. The total transaction value is approximately $1.075 billion and will be paid through a combination of cash and a $50 million seller note. This strategic move highlights Thermo Fisher’s ongoing focus on portfolio optimization and capital allocation aimed at enhancing long-term shareholder value.
The microbiology division being sold plays a key role in providing antimicrobial susceptibility testing solutions as well as culture media products. These offerings are widely used across clinical diagnostics, pharmaceutical research, and food safety testing, making the business an important contributor to quality control and healthcare outcomes. In 2025, the unit generated revenues of approximately $645 million and currently operates within Thermo Fisher’s Specialty Diagnostics segment.
Marc N. Casper, Chairman and Chief Executive Officer of Thermo Fisher Scientific, emphasized that the divestiture aligns with the company’s proactive approach to managing its business portfolio. He noted that the transaction will allow Thermo Fisher to unlock additional capital that can be reinvested into higher-growth areas, innovation initiatives, and other strategic priorities. Casper also expressed confidence that the microbiology business will thrive under Astorg’s ownership, citing strong alignment between the business’s capabilities and Astorg’s investment focus.
Astorg, known for investing in healthcare and technology-driven companies across Europe, is expected to provide the microbiology unit with resources and strategic direction to accelerate its growth trajectory. Thermo Fisher conveyed optimism regarding a seamless transition process for employees, customers, and stakeholders associated with the business. The company extended its best wishes to the team moving forward under the new ownership structure.
The transaction is anticipated to close in the second half of 2026, subject to the fulfillment of customary closing conditions, including regulatory approvals. From a financial perspective, Thermo Fisher expects the deal to have a modest dilutive effect on its adjusted earnings per share, estimated at $0.15 in the first full year after completion. Despite this short-term impact, the company views the divestiture as a value-enhancing step over the longer term.
Further details regarding how this transaction will influence Thermo Fisher’s financial outlook for 2026 are expected to be shared during the company’s upcoming second-quarter earnings call. Overall, the sale represents a strategic repositioning effort, enabling Thermo Fisher to sharpen its focus on core growth areas while ensuring that the microbiology business is placed in an environment where it can continue to expand and innovate effectively.
